Major Advance: PARP Inhibitor Pill Extends Life For Women With High Risk Breast Cancer & BRCA Mutations

Updated June 5th, 2021

Major Advance: PARP Inhibitor Pill Extends Life For Women With High Risk Breast Cancer & BRCA Mutations

A major new study has found that for women with early stage breast cancer classified as (HER2)–negative, who also have one of the mutations from the BRCA gene, a relatively new class of drugs called PARP Inhibitors significantly extends life after initial treatment.

NOW
PLAYING
Kayleigh McEnany: Fear of Dating Post-Mastectomy Delayed Breast Cancer Surgery
NOW
PLAYING
New Hope For Some Early-Stage Breast Cancer Patients: FDA Approves Targeted Therapy Drug Verzenio
NOW
PLAYING
It’s National Breast Cancer Awareness Month; Here Are Four Treatment & Screening Advancements Grabbing the Attention of Oncologists
NOW
PLAYING
Breast Cancer Survivor and Journalist Susan Berger Says Reporting on the PALB2 Mutation May Have Saved Her Life
NOW
PLAYING
ENHERTU Is A 'Big Game Changer' for HER2 Positive Metastatic Breast Cancer Patients
NOW
PLAYING
New Hope for Patients With Cervical Cancer: Adding Immunotherapy Drug to Standard Chemo Treatment Could Improve Survival Time

SurvivorNetTV.
Hope. Science.
Inspiration.

WATCH NOW
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.